MX369148B - Agentes de unión kir3dl2. - Google Patents

Agentes de unión kir3dl2.

Info

Publication number
MX369148B
MX369148B MX2015003476A MX2015003476A MX369148B MX 369148 B MX369148 B MX 369148B MX 2015003476 A MX2015003476 A MX 2015003476A MX 2015003476 A MX2015003476 A MX 2015003476A MX 369148 B MX369148 B MX 369148B
Authority
MX
Mexico
Prior art keywords
antibodies
binding agents
kir3dl2 binding
derivatives
methods
Prior art date
Application number
MX2015003476A
Other languages
English (en)
Other versions
MX2015003476A (es
Inventor
Gauthier Laurent
Kollnberger Simon
Rossi Benjamin
Sicard Hélène
Paturel Carine
Cornen Stéphanie
Zerbib Stéphanie
Original Assignee
Innate Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma filed Critical Innate Pharma
Publication of MX2015003476A publication Critical patent/MX2015003476A/es
Publication of MX369148B publication Critical patent/MX369148B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a métodos para el tratamiento de cáncer y enfermedad inflamatoria usando anticuerpos (por ejemplo, anticuerpos monoclonales), fragmentos de anticuerpos y derivados de los mismos que se enlazan específicamente a KIR3DL2. La invención también se refiere a anticuerpos, células productoras de tales anticuerpos; métodos de fabricación de tales anticuerpos; fragmentos, variantes, y derivados de los anticuerpos; composiciones farmacéuticas que comprenden el mismo.
MX2015003476A 2012-09-19 2013-09-17 Agentes de unión kir3dl2. MX369148B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261702834P 2012-09-19 2012-09-19
PCT/EP2013/069302 WO2014044686A1 (en) 2012-09-19 2013-09-17 Kir3dl2 binding agents

Publications (2)

Publication Number Publication Date
MX2015003476A MX2015003476A (es) 2015-08-10
MX369148B true MX369148B (es) 2019-10-30

Family

ID=49226157

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015003476A MX369148B (es) 2012-09-19 2013-09-17 Agentes de unión kir3dl2.

Country Status (13)

Country Link
US (3) US10577419B2 (es)
EP (1) EP2897980B1 (es)
JP (1) JP6507097B2 (es)
CN (1) CN104640880B (es)
AU (1) AU2013320360B2 (es)
BR (1) BR112015006060B1 (es)
CA (1) CA2881765C (es)
DK (1) DK2897980T3 (es)
ES (1) ES2770399T3 (es)
IL (1) IL237220B (es)
MX (1) MX369148B (es)
RU (1) RU2682449C2 (es)
WO (1) WO2014044686A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9181341B2 (en) * 2009-01-19 2015-11-10 Innate Pharma Anti-KIR3D antibodies
CN104640880B (zh) 2012-09-19 2020-06-09 先天制药公司 Kir3dl2结合剂
ES2878749T3 (es) 2013-02-20 2021-11-19 Innate Pharma Un compuesto que se une específicamente a KIR3DL2 para el uso en el tratamiento de linfoma de células T periférico
WO2015136052A1 (en) 2014-03-14 2015-09-17 Innate Pharma Humanized antibodies with increased stability
US10519234B2 (en) 2014-06-27 2019-12-31 Innate Pharma NKp46 binding proteins
WO2015197598A2 (en) 2014-06-27 2015-12-30 Innate Pharma Multispecific antigen binding proteins
WO2016030488A1 (en) * 2014-08-27 2016-03-03 Innate Pharma Treatment of celiac disease
EP3307784B1 (en) 2015-06-10 2021-12-22 National Research Council of Canada Carbonic anhydrase ix-specific antibodies and uses thereof
AU2016284866B2 (en) 2015-06-23 2022-09-29 Innate Pharma Multispecific antigen binding proteins
WO2016207278A1 (en) 2015-06-23 2016-12-29 Innate Pharma Multispecific nk engager proteins
WO2017156423A2 (en) * 2016-03-11 2017-09-14 Integrated Biotherapeutics, Inc. Broadly protective antibody cocktails for treatment of filovirus hemorrhagic fever
US10858431B2 (en) * 2016-06-30 2020-12-08 Trellis Bioscience, Llc Monoclonal antibodies targeting killer immunoglobulin-like receptor (KIR) family signaling
WO2018073363A1 (en) 2016-10-21 2018-04-26 Innate Pharma Treatment with anti-kir3dl2 agents
WO2018115262A1 (en) 2016-12-23 2018-06-28 Innate Pharma Heterodimeric antigen binding proteins
CA3052291A1 (en) * 2017-02-09 2018-08-16 Memorial Sloan Kettering Cancer Center Anti-kir3dl1 antibodies
CA3064443A1 (en) * 2017-05-24 2018-11-29 Development Center For Biotechnology Humanized antibodies against globo h and uses thereof in cancer treatments
CN111093701A (zh) * 2017-06-15 2020-05-01 财团法人生物技术开发中心 含有抗globo h抗体的抗体药物偶联物及其用途
CA3068056A1 (en) * 2017-06-22 2018-12-27 Development Center For Biotechnology Asymmetric heterodimeric fc-scfv fusion anti-globo h and anti-cd3 bispecifc antibody and uses thereof in cancer therapy
EP3713959A1 (en) 2017-11-21 2020-09-30 Innate Pharma Multispecific antigen binding proteins
WO2019156223A1 (ja) * 2018-02-09 2019-08-15 国立大学法人大阪大学 チクングニアウイルスに対する抗体またはその抗原結合断片、およびその用途
WO2020035345A1 (en) 2018-08-14 2020-02-20 Innate Pharma Treatment of colorectal cancer by a combination of an anti-mica antibody and an anti-nkg2a antibody
WO2020152081A1 (en) 2019-01-22 2020-07-30 Innate Pharma Treatment of t cell lymphoma
WO2021067633A2 (en) 2019-10-04 2021-04-08 Albert Einstein College Of Medicine Kir3dl3 is an inhibitory receptor of the immune system and uses thereof
CN110950960B (zh) * 2019-11-26 2021-05-14 中国农业大学 基于高通量测序和杂合杂交瘤技术的小分子化合物抗体的制备方法
TW202202521A (zh) * 2020-03-23 2022-01-16 美商必治妥美雅史谷比公司 用於治療癌症之抗ccr8抗體
AU2022218137A1 (en) 2021-02-03 2023-08-24 Mozart Therapeutics, Inc. Binding agents and methods of using the same
KR20230162013A (ko) 2021-03-26 2023-11-28 이나뜨 파르마 에스.에이. Nk 세포 관여를 위해 사이토카인에 융합된 nkp46-결합 부위, 암 항원 결합 부위를 포함하는 다중특이적 단백질
AU2022255908A1 (en) 2021-04-05 2023-10-05 Innate Pharma Immunohistochemistry methods and kir3dl2-specific reagents
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
MX2023014645A (es) 2021-06-09 2024-01-31 Innate Pharma Proteinas acopladoras de celulas nk de union a nkp46 especificas de cd20.
CN117616050A (zh) 2021-06-09 2024-02-27 先天制药公司 与nkp46、细胞因子受体、肿瘤抗原和cd16a结合的多特异性蛋白质
CN113248609B (zh) * 2021-07-14 2021-09-10 深圳市盛波尔生命科学技术有限责任公司 针对再生胰岛衍生蛋白1α的抗体组合以及包含其的检测试剂盒
CA3227845A1 (en) * 2021-07-30 2023-02-02 R.P. Scherer Technologies, Llc Antibody-drug conjugates and methods of use thereof
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
CN119998330A (zh) 2022-09-15 2025-05-13 艾维迪治疗知识产权有限公司 用于刺激nk细胞的多特异性抗原结合蛋白及其用途
WO2024251884A1 (en) 2023-06-09 2024-12-12 Innate Pharma Nk cell engager proteins comprising anti-cd20 and ant-nkp46 antibody, linked to il-2 in treatment of r/r b-nhl
CN117801108B (zh) * 2023-12-06 2024-06-07 无锡傲锐东源生物科技有限公司 抗人mdm2蛋白单克隆抗体及其杂交瘤细胞株和应用
WO2025191133A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof
WO2025191137A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Conjugates of trop2-specific antigen binding proteins and cytokines
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
WO2025245386A1 (en) * 2024-05-23 2025-11-27 La Jolla Institute For Immunology Kir3dl2 as an anti-cancer target

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004528824A (ja) 2000-12-18 2004-09-24 アーンスティテュ ナシオナール ド ラ サント エ ド ラ ルシェルシェ メディカル（イー．エンヌ．エス．ウー．エール．エンム．） 皮膚ｔ細胞リンパ腫（ｃｔｃｌ）の新規な診断及び治療法
KR101420344B1 (ko) * 2003-07-02 2014-07-16 위니베르시따 디 제노바 Ｐａｎ-ｋｉｒ2ｄｌ ｎｋ-수용체 항체 및 진단 및 치료에서의 그 사용 방법
US9181341B2 (en) 2009-01-19 2015-11-10 Innate Pharma Anti-KIR3D antibodies
WO2011027310A1 (en) * 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
US20130315933A1 (en) * 2010-10-06 2013-11-28 Christoph Renner Antibodies Directed Against HLA-B27 Homodimers and Methods and Uses Thereof in Diagnosis and Therapy
CN104640880B (zh) 2012-09-19 2020-06-09 先天制药公司 Kir3dl2结合剂
WO2014044681A1 (en) * 2012-09-19 2014-03-27 Innate Pharma Kir3dl2 binding agents
ES2878749T3 (es) 2013-02-20 2021-11-19 Innate Pharma Un compuesto que se une específicamente a KIR3DL2 para el uso en el tratamiento de linfoma de células T periférico
JP6865582B2 (ja) * 2013-05-29 2021-04-28 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｋｉｒ３ｄｌ２は皮膚及び非皮膚末梢ｔ細胞リンパ腫のサブセットをそれぞれ予防及び治療するために有用なバイオマーカー及び治療標的である
WO2015136052A1 (en) 2014-03-14 2015-09-17 Innate Pharma Humanized antibodies with increased stability
WO2018073363A1 (en) 2016-10-21 2018-04-26 Innate Pharma Treatment with anti-kir3dl2 agents

Also Published As

Publication number Publication date
MX2015003476A (es) 2015-08-10
US20150232556A1 (en) 2015-08-20
ES2770399T3 (es) 2020-07-01
WO2014044686A1 (en) 2014-03-27
US20240124579A1 (en) 2024-04-18
US10577419B2 (en) 2020-03-03
EP2897980B1 (en) 2019-11-06
RU2682449C2 (ru) 2019-03-19
CA2881765C (en) 2024-02-13
RU2015104760A (ru) 2016-11-10
IL237220A0 (en) 2015-04-30
US11858990B2 (en) 2024-01-02
AU2013320360B2 (en) 2018-06-14
EP2897980A1 (en) 2015-07-29
JP6507097B2 (ja) 2019-04-24
DK2897980T3 (da) 2020-02-17
CN104640880A (zh) 2015-05-20
CN104640880B (zh) 2020-06-09
BR112015006060A2 (pt) 2018-09-25
BR112015006060B1 (pt) 2023-03-21
JP2015535820A (ja) 2015-12-17
IL237220B (en) 2020-02-27
CA2881765A1 (en) 2014-03-27
US20200199228A1 (en) 2020-06-25
AU2013320360A1 (en) 2015-03-05

Similar Documents

Publication Publication Date Title
MX369148B (es) Agentes de unión kir3dl2.
IN2014KN00848A (es)
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
PH12014502527A1 (en) St2 antigen binding proteins
PH12017500864A1 (en) Anti-notch1 antibodies
MX2019006362A (es) Una combinacion de inmunoconjugado y anticuerpo para usarse en el tratamiento de cancer.
JOP20210044A1 (ar) الأجسام المضادة لـ cd38
MX2010010387A (es) Anticuerpos especificos para el complejo de bcr y metodos para el uso de los mismos.
SG178886A1 (en) Humanized anti-cdcp1 antibodies
PH12013500810B1 (en) Anti-il-23 antibodies
PH12014502406A1 (en) Anti-il-23p19 antibodies
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
WO2011004028A3 (en) Tlr3 binding agents
WO2014163714A3 (en) Antibody drug conjugates
EP2579895A4 (en) ANTI-VEGF ANTIBODIES AND USES THEREOF
TN2012000466A1 (en) Humanized anti cxcr4 antibodies for the treatment of cancer
PH12015501360A1 (en) Bmp-6 antibodies
MY158481A (en) Compositions and methods for treating inflammatory disorders
MX360163B (es) Moleculas de union il-6.
PH12013500432A1 (en) Anti-vegfr-3 antibody compositions
EP2596365A4 (en) MONOCLONAL ANTIBODIES TO PCBP1 ANTIGENES AND APPLICATIONS THEREOF
HK1196856A (en) C10rf32 antibodies, and uses thereof for treatment of cancer
TN2013000068A1 (en) Anti-vegfr-3 antibody compositions
TN2013000186A1 (en) Anti-il-23 antibodies

Legal Events

Date Code Title Description
FG Grant or registration